	US 11,850,254 B2
	Tryptamine compositions for enhancing neurite outgrowth
Paul Edward Stamets, Shelton, WA (US)
Assigned to TURTLE BEAR HOLDINGS, LLC, Shelton, WA (US)
Filed by TURTLE BEAR HOLDINGS, LLC, Shelton, WA (US)
Filed on Feb. 11, 2022, as Appl. No. 17/669,919.
Application 17/669,919 is a continuation of application No. 16/951,009, filed on Nov. 18, 2020, granted, now 11,660,305.
Claims priority of provisional application 63/007,482, filed on Apr. 9, 2020.
Claims priority of provisional application 62/937,536, filed on Nov. 19, 2019.
Prior Publication US 2022/0160737 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/661 (2006.01); A61K 36/07 (2006.01); A61K 36/73 (2006.01); A61P 25/24 (2006.01); A61K 31/352 (2006.01); A61K 31/455 (2006.01); A61K 36/066 (2006.01); A61K 31/05 (2006.01); A61K 9/08 (2006.01); A61K 31/4045 (2006.01); A61K 36/06 (2006.01); A61K 36/185 (2006.01)

CPC A61K 31/661 (2013.01) [A61K 9/08 (2013.01); A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61K 31/4045 (2013.01); A61K 31/455 (2013.01); A61K 36/06 (2013.01); A61K 36/066 (2013.01); A61K 36/07 (2013.01); A61K 36/185 (2013.01); A61K 36/73 (2013.01); A61P 25/24 (2018.01)]

16 Claims

1. A pharmaceutical composition comprising:

0.1 mg to 10 mg of N-methyl-3,4-methylenedioxy-amphetamine (MDMA);

0.1 mg to 10 mg of niacin; and

0.1 mg to 10 mg of a tryptamine selected from norpsilocin, psilocin or psilocybin, norbaeocystin, aeruginascin, or a pharmaceutically acceptable salt thereof.